Start Your Search
MTE 06 - Survivorship After Combined Modality Therapy (Imaging, Salvage Therapy) (Ticketed Session) (ID 58)
- Event: WCLC 2015
- Type: Meet the Expert (Ticketed Session)
- Track: Treatment of Locoregional Disease – NSCLC
- Presentations: 1
- Coordinates: 9/07/2015, 07:00 AM - 08:00 AM, 102+104+106
MTE06.01 - Curative Radiotherapy for Local or Locoregional Disease (ID 1985)
07:00 - 07:30 AM | Author(s): Y. Nagata
Radiation and chemotherapy are usually combined in the treatment of locally advanced lung cancer. Therefore, survivorship after chemoradiotherapy is important. The most frequent pattern of failure is distant metastases, followed by lymph nodal failure and local failure. Periodical examination by CT and/or FDG-PET as imaging method is important. However, its optimal frequency and timing are still unknown. Palliative radiotherapy is indicated for several metastases. Stereotactic radiosurgery (SRS) is usually indicated for single or multiple brain metastases less than 4 in number. Whole brain radiotherapy is indicated for multiple brain metastases. Single or fractionated radiotherapy is indicated for bone metastases in combination with Zoledronic acid Hudrates. Strontium-90 can be indicated for multiple bone metastases when tumor has its uptake. Stereotactic body radiotherapy (SBRT) is a technique, introduced in the late 1990s. SBRT is a method of using single 10-20Gy of high dose and hypofractionated radiotherapy. Recently, many papers have been published on its clinical results, especially in early stage lung cancer. SBRT can also be used for lung metastases.
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.